The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting Novo Nordisk's push to capture more of the growing weight-loss drug market, the company's top US executive said it hopes insurance will cover more users of Wegovy in America, according to Reuters. The executive added that broader insurance coverage would balance direct-to-consumer sales and expand access to a wider patient base.
The statement comes as the obesity drug market expands rapidly, with rising competition from rivals like Eli Lilly. NVO shares closed at $47.42 on June 23, 2026, showing stable performance, per market data. Analysts believe successful expansion of insurance coverage could significantly broaden Wegovy's user base.
In recent trading, the stock ranged between $46.44 and $47.43, indicating relative stability. Investors are watching for outcomes of negotiations with insurers and any regulatory developments, as well as upcoming second-quarter earnings reports that may provide further clues on Wegovy sales growth.
Sign in to access this content
Sign In